NATCO launches additional strengths for the Generic Version of Revlimid® in USA

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces the launch of additional strengths for the generic version of Revlimid® (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Revlimid® is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 560.25 as compared to the previous close of Rs. 568.00. The total number of shares traded during the day was 10573 in over 683 trades.

The stock hit an intraday high of Rs. 574.95 and intraday low of 556.20. The net turnover during the day was Rs. 5971592.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 AdditionalStrengths LenalidomideCapsules USA